Potential Prophylactic and Therapeutic Vaccines for HSV Infections

Author(s): Srividya Ramachandran, Paul R. Kinchington

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 19 , 2007

Become EABM
Become Reviewer
Call for Editor


The human herpesviruses herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) can cause severe recurrent disease in humans and establish lifelong infection in their hosts. Several antiviral therapies are available to control disease and spread, but these are not completely effective and do not affect latent virus. The need for vaccines for HSV is urgent, both for controlling initial infection and spread of disease as well as to limit recurrences. Several approaches including subunit vaccines, peptide vaccines, live virus vectors and DNA vaccine technology have been used in developing both prophylactic and therapeutic vaccines for HSV and these are reviewed here.

Keywords: interferons, adaptive immune response, Peptide Vaccines, disabled infectious single cycle viruses, HSV DNA, Live Virus Vaccines

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Published on: 01 March, 2012
Page: [1965 - 1973]
Pages: 9
DOI: 10.2174/138161207781039760
Price: $65

Article Metrics

PDF: 4